A themed research selection of Kisspeptin-10, two NAD+ vials, GLOW and GLP-3 (retatrutide). It brings reproductive signalling, cellular redox chemistry and metabolic receptor research into view for readers interested in menopause-related scientific questions.
CURATED INDIVIDUAL ITEMS · TEST / DEMOAT A GLANCE
Inside the stack
Kisspeptin-10
1 × 10 mg single vial · $109.99 CAD each
$109.99 CAD
Kisspeptin-10 is a short kisspeptin fragment used to explore reproductive-hormone signalling. Its interest centres on the kisspeptin receptor and upstream regulation of the reproductive axis.
Reproductive-axis signalling — The kisspeptin system connects upstream signals with GnRH-related endocrine biology.
Short-fragment identity — KP-10 is a ten-amino-acid fragment, distinct from kisspeptin-54.
Hormone physiology — Reviewed acute KP-10 experiments in healthy men measured luteinizing hormone and its pulse pattern; this is distinct from kisspeptin-54 evidence.
NAD+ is a coenzyme at the centre of cellular redox chemistry. Its role in electron transfer makes it a foundational material for exploring energy metabolism and enzyme activity.
Redox reactions — Nicotinamide adenine dinucleotide participates in electron-transfer reactions.
Energy metabolism — NAD-dependent reactions connect nutrient processing with cellular energy chemistry.
Coenzyme research — A non-peptide identity supports biochemical questions distinct from receptor-targeting peptides.
GLOW is the catalogue’s 70 mg multi-peptide blend, presented within matrix-related research selections. Its complete strength is listed; verified component identities and ratios are needed to describe individual roles responsibly.
Listed formulation — 70 mg describes the entire blend, not the strength of each constituent.
Component documentation — The retail fixture does not supply confirmed constituents or proportions; no component effect is assigned here.
GLP-3 is the catalogue name for retatrutide, a GIP, GLP-1 and glucagon receptor triple agonist. Controlled clinical research examines metabolic and body-weight endpoints for the investigational molecule.
Three receptor targets — GIP, GLP-1 and glucagon receptor activity frame its metabolic research identity.
Metabolic-health research — Reviewed trials investigate body-weight endpoints in defined populations.
Clinical evidence — Trial interventions and monitored participants are distinct from a catalogue vial or pen.
Kisspeptin-10 introduces reproductive-axis signalling; NAD+ supplies a redox-chemistry perspective; retatrutide engages GIP, GLP-1 and glucagon receptors. GLOW is the listed 70 mg blend, whose component identities and proportions require documentation. This theme is not an approved menopause therapy or a study of these materials together.
Explore the evidence & study context
Kisspeptin-10
Human physiology
Kisspeptin-10 produced a rapid rise in measured luteinizing hormone in the 2011 experiments.
An acute hormone response is not a demonstrated fertility or sexual-performance benefit.
Coenzyme (not a peptide) · redox and energy-metabolism research
No reviewed study findings supplied for this identity. Parent-peptide evidence is not a substitute.
GLOW
Multi-peptide blend
No reviewed study findings supplied for this identity. Parent-peptide evidence is not a substitute.
GLP-3
Human trial
Jastreboff et al. (NEJM, 2023) randomized 338 adults with obesity, or overweight plus a weight-related condition, in a 48-week phase 2 trial.
Receptor activity concerns metabolic signalling; measured weight change is a separate endpoint, not proof of an appetite mechanism or a PEPTIVIA product effect.
At week 48, least-squares mean body-weight change was −24.2% in the investigational 12 mg arm (starting at 2 mg), versus −2.1% with placebo; week 24 was the primary endpoint.
This is a specific trial arm and secondary endpoint, not expected weight loss from a purchased vial or a use recommendation.
The stack contains separately labelled vials, not one combined mixture. A constituent such as GLOW or CJC/ipamorelin is itself a premixed blend, as named in the catalogue.
How is the price calculated?
The selected total is the sum of the current retail price of each constituent vial, multiplied by its displayed quantity. Two vials means two single-vial prices, not a bulk tier. No additional stack discount is applied.
Does adding this change a paid order?
No. The items enter your current demo bag together. Existing bag lines increase by their stated quantities; paid test orders remain unchanged. Checkout is simulated.
What handling information is available?
Format, strength and quantity are shown for each item. Storage, identity, purity and handling require verified batch-specific documentation. This collection supplies no dosing or cycle schedule.
Can component evidence prove the collection works?
No. Study findings retain their individual experimental context. A shared research theme does not establish the effects or safety of a combination.
Selank and Semax bring two complementary research questions into view: GABA-related signalling and neurotrophic pathways involved in learning and memory. A focused starting point for exploring stress-response and cognitive neuroscience.
Explore growth-hormone signalling and cellular adaptation with two vials each of CJC-1295 with DAC, ipamorelin and MOTS-c. This collection brings growth-axis and mitochondrial research into one clearly specified selection.